• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

PLx Pharma prices $63M offering

March 3, 2021 By Sean Whooley

PLx PharmaPLx Pharma (NSDQ:PLXP) announced today that it priced an underwritten public offering worth approximately $63 million.

Sparta, N.J.-based PLx Pharma is offering 7.875 million shares of its common stock priced at $8 per share to the public, according to a news release.

Additionally, the company granted underwriters a 30-day option to purchase up to more than 1.18 million more shares of common stock at the public offering price. The company is offering all shares.

PLx Pharma expects the offering to close on or about March 5, 2021, subject to customary closing conditions. The company anticipates gross proceeds of about $63 million before deductions, an amount that assumes no exercise of the underwriters’ option.

The company plans to use the net proceeds from the offering for general corporate purposes, including potential additions to working capital and capital expenditures.

Raymond James & Associates, Inc. and Oppenheimer & Co. Inc. are acting as joint book-running managers for the offering.

PLx Pharma develops the PLxGuard drug delivery platform designed to target the release of active pharmaceutical ingredients to various portions of the gastrointestinal tract to improve the absorption of many drugs and reduce the risk of stomach erosions and ulcers associated with certain drugs.

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Funding Roundup Tagged With: PLx Pharma

IN CASE YOU MISSED IT

  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott
  • Study links Abbott CGM use to lower risk of hospitalizations due to heart complications

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS